Showing results (71-80 of 82) with videos related to
Sort By:
Pageof 9
British Journal of Anaesthesia|February 4, 2026
Optimising protamine dosing for heparin reversal after cardiopulmonary bypass: a population pharmacokinetic-pharmacodynamic studyJulien Lanoiselée, Audrick Gibert, Isabelle Gouin-Thibault, et al.Journal of Thrombosis and Haemostasis : JTH|June 20, 2019
Rivaroxaban pharmacodynamics in healthy volunteers evaluated with thrombin generation and the active protein C system: Modeling and assessing interindividual variabilityVirginie Siguret, Johan Abdoul, Xavier Delavenne, et al.Thrombosis and Haemostasis|November 17, 2022
Assessment of DOAC in GEriatrics (Adage Study): Rivaroxaban/Apixaban Concentrations and Thrombin Generation Profiles in NVAF Very Elderly PatientsGeoffrey Foulon-Pinto, Carmelo Lafuente-Lafuente, Georges Jourdi, et al.Journal of Thrombosis and Haemostasis : JTH|July 17, 2024
Tinzaparin, an alternative to subcutaneous unfractionated heparin, in patients with severe and end-stage renal impairment: a retrospective observational single-center studyIsabelle Gouin-Thibault, Alexandre Mansour, Charlène Caribotti, et al.Research and Practice in Thrombosis and Haemostasis|June 11, 2025
Management of bleeding and invasive procedures in patients treated with anti-factor XI(a) anticoagulants: proposals from the French Working Group on Perioperative Haemostasis and French Society of Thrombosis and HaemostasisAnne Godier, Dominique Lasne, Anne-Céline Martin, et al.Journal of Thrombosis and Haemostasis : JTH|May 18, 2024
The use of 1E12, a monoclonal anti-platelet factor 4 antibody, to improve the diagnosis of vaccine-induced immune thrombotic thrombocytopeniaCaroline Vayne, Jérôme Rollin, Rumi Clare, et al.Chest|January 19, 2021
Impact of High-Dose Prophylactic Anticoagulation in Critically Ill Patients With COVID-19 PneumoniaCharles Tacquard, Alexandre Mansour, Alexandre Godon, et al.Thrombosis and Haemostasis|June 15, 2023
Factors Influencing Anti-Xa Assays: A Multicenter Prospective Study in Critically Ill and Noncritically Ill Patients Receiving Unfractionated HeparinDominique Lasne, Marie Toussaint-Hacquard, Céline Delassasseigne, et al.Blood Advances|May 27, 2026
A comprehensive multicenter study assessing the impact of abelacimab, asundexian and milvexian on coagulation assaysLaurie Goubeau, Emmanuel Curis, Xavier Delavenne, et al.Journal of Thrombosis and Haemostasis : JTH|August 11, 2024
Sensitivity and specificity of strategies to identify patients with hemostasis abnormalities leading to an increased risk of bleeding before scheduled intervention: the Hemorisk studyNadine Ajzenberg, Dan Longrois, Dorothée Faille, et al.Pageof 9